EUVIMEDEUVIMED entdecken
Crossref

Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists

Céline Delaitre, Michel Boisbrun iD, Samir Acherar iD, André Dias, Alexandra Kleinclauss, Mathilde Achard, Mélissa Colin, Trung Minh Nguyen, Nicolas Humbert, Khawla Chmeis, Karen L Martinez, Nicolas Gilles iD und 3 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Céline Delaitre und 14 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lorraine, CITHEFOR, Nancy F-54000, France. Hauptthemen laut MEDLINE: beta-Arrestins, Fluorescent Dyes, Receptor, Angiotensin, Type 1, Losartan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Minist?re de l'Enseignement sup?rieur, de la Recherche et de l'Innovation, Agence Nationale de la Recherche, Institut National de la Sant? et de la Recherche M?dicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin II (AngII) regulates cerebral circulation and binds with a similar affinity to AT1 and AT2 receptors. Biased AT1 agonists, such as TRV027, which are able to selectively activate β-arrestin while blocking the Gq pathway, appear promising as new therapeutics. New pharmacological tools are needed to further explore the impact of biased AT1 agonists on cells or tissues, such as the cerebral vessels. We designed and synthesized new fluorescent derivatives based on AngII, TRV027, or the AT1 antagonist losartan. We conducted pharmacological characterization to determine their selectivity, potency, and ability to activate or not specific AT1 transduction pathways in cells and cerebral arteries. We report the first highly AT1-selective fluorescent ligand, based on losartan, that retains its antagonist activity with high affinity. Fluorescent derivatives of TRV027 become AT2-selective and lose their AT1 β-arrestin bias. These new ligands can be applied to trace AT1 or AT2 receptors in vitro and ex vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ArrestinsFluorescent DyesReceptor, Angiotensin, Type 1LosartanLigandsHumansAnimalsHEK293 CellsAngiotensin IIStructure-Activity RelationshipAngiotensin II Type 1 Receptor BlockersReceptors, AngiotensinReceptor, Angiotensin, Type 2Male

Substanzen

beta-ArrestinsLigandsFluorescent DyesReceptor, Angiotensin, Type 1LosartanAngiotensin IIAngiotensin II Type 1 Receptor BlockersReceptors, AngiotensinReceptor, Angiotensin, Type 2

Autor:innen und Institutionen

  • Université de Lorraine, CITHEFOR, Nancy F-54000, France.
  • BSC UMR7242 "GPCRs, pain and inflammation" team, CNRS, Université de Strasbourg, Illkirch F-67412, France.
  • Université de Lorraine, CNRS, L2CM, Nancy F-54000, France.
  • Université de Lorraine, CNRS, LCPM, Nancy F-54000, France.
  • Department of Chemistry and Nano-Science Center, University of Copenhagen, Thorvaldsensvej 40, Frederiksberg 1871, Denmark.
  • Laboratory de Bioimaging and Pathology, CNRS UMR 7021, Faculty of pharmacy, Université de Strasbourg, Illkirch F-67412, France.

ORCID-Profile: Michel Boisbrun, Samir Acherar, Nicolas Gilles, François Dupuis

Förderung

  • Minist?re de l'Enseignement sup?rieur, de la Recherche et de l'Innovation
  • Agence Nationale de la Recherche
  • Institut National de la Sant? et de la Recherche M?dicale
  • Universit? de Strasbourg
  • Universit? de Lorraine
  • Novo Nordisk Fonden
  • European Cooperation in Science and Technology
  • Centre National de la Recherche Scientifique

Zitieren

APA

Delaitre, C., Boisbrun, M., Acherar, S., Dias, A., Kleinclauss, A., Achard, M., Colin, M., Nguyen, T. M., Humbert, N., Chmeis, K., Martinez, K. L., Gilles, N., Robin, P., Lecat, S., & Dupuis, F. (2024). Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01693

Vancouver

Delaitre C, Boisbrun M, Acherar S, Dias A, Kleinclauss A, Achard M, et al. Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01693

BibTeX
@article{Delaitre2024,
  author = {Delaitre, Céline and Boisbrun, Michel and Acherar, Samir and Dias, André and Kleinclauss, Alexandra and Achard, Mathilde and Colin, Mélissa and Nguyen, Trung Minh and Humbert, Nicolas and Chmeis, Khawla and Martinez, Karen L and Gilles, Nicolas and Robin, Philippe and Lecat, Sandra and Dupuis, François},
  title = {Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β-Arrestin-Biased Agonists, and Antagonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01693}
}
Kostenlos starten →